Identification of paediatric Hodgkin lymphoma biomarkers and novel therapeutic targets.
- Conditions
- 10025319Hodgkin diseaseHodgkin lymphomamalignant lymphoma
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 230
In order to be eligible to participate in the Hodgkin lymphoma group, a subject
must meet all of the following criteria:
• Diagnosis of classical Hodgkin Lymphoma confirmed by reference pathology
• Patient aged below 18 at time of diagnosis
· Treatment according the European Network of Paediatric Hodgkin`s Lymphoma
Second International Inter-Group Study for Classical Hodgkin*s Lymphoma in
Children and Adolescents (EuroNet-PHL-C2) protocol or treatment for relapsed or
refractory patients or according to the Open-label, Uncontrolled, Multicenter
Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with
Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early)
Response to Frontline Chemotherapy.
• Written informed consent of the patient and/or the patient's parents or
guardians according to national laws
- HIV positivity
- Other underlying immunologic disorders causing an inadequate or overactive
immune response, with the exception of Epstein Barr Virus
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method